Chemoembolization for Liver Tumor at Medias Clinic Burghausen

At the Medias Clinic in Burghausen, Germany, the treatment of primary liver cancer and metastatic liver disease is redefined through a high-precision procedure known as transarterial chemoembolization (TACE). Under the direction of Prof. Dr. Karl R. Aigner, this intervention is designed for patients with inoperable tumors who require a more aggressive local impact than standard systemic chemotherapy can provide. The core of the TACE offer lies in its one-two punch mechanics: a specialized catheter is guided through the femoral artery into the hepatic artery, where a potent chemotherapy mixture, often including doxorubicin or cisplatin, is delivered alongside embolic microspheres. These tiny particles trap the medicine within the tumor while simultaneously cutting off the oxygen and nutrient supply the malignancy needs to survive. The data supporting this approach highlight its ability to manage high-burden disease with significantly lower systemic toxicity. For patients with unresectable hepatocellular carcinoma (HCC), research on regional chemoembolization has shown impressive survival benefits; for instance, longitudinal studies have reported survival rates of up to 70% at 15 months in select patient groups. Furthermore, for those with intrahepatic cholangiocarcinoma who have not responded to standard IV treatments, TACE has demonstrated a local tumor control rate of approximately 93%. By keeping the chemotherapy concentrated within the liver’s isolated perfusion bed, the medical team can achieve a tumor-killing effect that is exponentially higher than traditional methods, often leading to significant tumor shrinkage or the resolution of painful symptoms like ascites. In addition, Medias Clinic focuses on the downstaging of liver tumors to make them eligible for surgical removal. This conversion therapy is a hallmark of the approach, turning once-terminal cases into candidates for curative resection. Because the liver has a unique dual blood supply, receiving nutrients from the portal vein while the tumor relies almost exclusively on the hepatic artery, the TACE procedure can starve the cancer while sparing the healthy liver tissue. This allows patients to undergo repeated cycles of treatment if necessary without the cumulative, body-wide exhaustion typical of systemic drugs.